Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Focal Onset Seizures
Interventions: XEN1101, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: QVA149, QAB149, NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 56
States / cities: Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPD489 (Lisdexamfetamine dimesylate), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 55
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 51 more

Conditions: Long QT Syndrome
Interventions: GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 49
States / cities: Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more

Conditions: Type 2 Diabetes Mellitus
Interventions: MBX-2044, Placebo for MBX-2044; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Myocardial Ischemia
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy
Interventions: THB335 single dose, Single dose placebo, THB335 fasted/fed, Placebo fasted/fed, THB335 multiple dose, Multiple dose placebo; Drug
Lead sponsor: Third Harmonic Bio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: VEXAS, VEXAS Syndrome
Interventions: Pacritinib, Placebo; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more

Conditions: Healthy
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Marginal Ulcer
Interventions: Omeprazole 40 milligrams; Drug
Lead sponsor: Stephen Firkins; Other
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: HQK-1001, placebo; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Osteopenia, Osteoporosis
Interventions: Micronized Calcium Carbonate, Non-Micronized Calcium Carbonate, Vitamin D3; Dietary Supplement
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atrial Fibrillation
Interventions: Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Female Sexual Health
Interventions: KSM-66 Ashwagandha® capsule, Identical Placebo capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Covid19
Interventions: Placebo injection and placebo pill, Estradiol Cypionate 5 mg/ml, Progesterone 200 mg Oral Capsule; Other · Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Papulopustular Rosacea
Interventions: DFD-29, Doxycycline, Placebo; Drug
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more

Conditions: Alzheimer Disease, Dementia
Interventions: MK-1167, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Phoenix, Arizona • Irvine, California • Redlands, California + 25 more

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Non-small Cell Lung Cancer Stage III
Interventions: Paclitaxel, Placebo for Veliparib, Carboplatin, Veliparib, Radiotherapy; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 12
States / cities: La Jolla, California • Newark, Delaware • Chicago, Illinois + 8 more

Conditions: Dental Pain
Interventions: Celecoxib 400 mg, Placebo, Indomethacin Test (lower dose), Indomethacin Test (upper dose); Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rheumatoid Arthritis
Interventions: Meriva, placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions: ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment); Dietary Supplement · Other
Lead sponsor: Arbor Life Labs; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alcohol Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

A First in Human Trial Evaluating THB335 in Healthy Participants

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Effect of Single Dose of Ashwagandha Root Extract on Sexual Health in Women.

Estradiol and Progesterone in Hospitalized COVID-19 Patients

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

Curcuma Longa L in Rheumatoid Arthritis

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder